Further analysis has shown that GLP-1 receptor agonist use is in fact associated with consistently reduced risk of pancreatic cancer compared to use of 6 other classes of antidiabetic medications, and the benefits were greater in those with concurrent obesity and tobacco use.9 Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.